NERV
NASDAQMinerva Neurosciences Inc
Website
News25/Ratings2
News · 26 weeks54+27%
2025-10-262026-04-19
Mix3090d
- SEC Filings16(53%)
- Other9(30%)
- Insider3(10%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form DEFA14A filed by Minerva Neurosciences IncDEFA14A - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECSEC Form DEF 14A filed by Minerva Neurosciences IncDEF 14A - Minerva Neurosciences, Inc. (0001598646) (Filer)
- INSIDERSEC Form 4 filed by O'Connor James Joseph4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- INSIDERSEC Form 3 filed by new insider O'Connor James Joseph3 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- ANALYSTCitizens initiated coverage on Minerva Neurosciences with a new price targetCitizens initiated coverage of Minerva Neurosciences with a rating of Mkt Outperform and set a new price target of $14.00
- SECSEC Form PRE 14A filed by Minerva Neurosciences IncPRE 14A - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECSEC Form 8-K filed by Minerva Neurosciences Inc8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECMinerva Neurosciences Inc filed SEC Form 8-K: Regulation FD Disclosure8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- PRMinerva Announces Leadership TransitionBURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced a leadership transition with the appointment of Jim O'Connor as Chief Business Officer (CBO), effective April 21, 2026, as Geoff Race, the Company's President, has elected to leave the company. Mr. Race will continue to be involved with Minerva as a consultant. Mr. Race joined Minerva in 2010 and went on to serve in multiple executive roles including Executive Vice President and Chief Financial Officer, Chief Business Officer, and most recently President
- INSIDERSEC Form 4 filed by Kaul Inderjit4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)
- SECSEC Form 144 filed by Minerva Neurosciences Inc144 - Minerva Neurosciences, Inc. (0001598646) (Subject)
- SECSEC Form 144 filed by Minerva Neurosciences Inc144 - Minerva Neurosciences, Inc. (0001598646) (Subject)
- SECSEC Form 144 filed by Minerva Neurosciences Inc144 - Minerva Neurosciences, Inc. (0001598646) (Subject)
- PRMinerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of SchizophreniaRoluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2H 2027 BURLINGTON, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia. Negative symptoms, including avolition (severe lack of motivat
- PRMinerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the second half of 2027 BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the presentation of clinical data from its open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25
- SECSEC Form EFFECT filed by Minerva Neurosciences IncEFFECT - Minerva Neurosciences, Inc. (0001598646) (Filer)
- PRMinerva Neurosciences to Participate in The Stifel 2026 Virtual CNS ForumBURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Stifel 2026 Virtual CNS Forum being held March 17-18, 2026. The Stifel 2026 Virtual CNS ForumFormat:Company presentationDay/Time:Wednesday, March 18 at 8.30 AM ETWebcast:Webcast Link:https://event.summitcast.com/view/4Ggc9Rmi4GQpDPGZwDp8g8/DdYPDYEQLLU6kp2AWRS6bu If you are interested in a virtual meeting with the Minerva team during the conference, please re
- SECSEC Form S-3 filed by Minerva Neurosciences IncS-3 - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECSEC Form 10-K filed by Minerva Neurosciences Inc10-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- SECMinerva Neurosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)
- PRMinerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business UpdatesBURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today provided business updates and reported financial results for the fourth quarter and year ended December 31, 2025. Business Updates Strategic Financing On October 23, 2025, Minerva received $80.0 million in gross proceeds from a private placement, before deducting fees and other expenses. The financing included initial upfront funding of $80.0 million and up to an additional $80.0 million if all Tranche A warrants are exercised, subject to the terms and co
- SECSEC Form 144 filed by Minerva Neurosciences Inc144 - Minerva Neurosciences, Inc. (0001598646) (Subject)
- SECSEC Form 144 filed by Minerva Neurosciences Inc144 - Minerva Neurosciences, Inc. (0001598646) (Subject)
- SECSEC Form 144 filed by Minerva Neurosciences Inc144 - Minerva Neurosciences, Inc. (0001598646) (Subject)
- PRMinerva Neurosciences to Participate in The Citizens Life Sciences ConferenceBURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami, FL. The Citizens Life Sciences ConferenceFormat:Company presentationDay/Time: Tuesday, March 10 at 9:35 AM ETWebcast:https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/SKrutqyvQVtnaKJDseE6uU If you are interested in meeting with the Minerva team during the conference, please reach